Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched generic treatment is for migraine, Axert (almotriptan malate) tablets in 6.25 mg and 12.5 mg dosages, in the US.
Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Teva continues to deliver on its generics business strategy and remains focused on increasing its first to file regulatory submissions in the US. With over 375 generic medicines available, Teva has the largest portfolio of safe, effective, US Food and Drug Administration (FDA) -approved generic products on the market.
Axert (almotriptan malate) tablets, marketed by Janssen Pharmaceuticals, had annual sales of approximately $31 million in the US, according to IMS data as of March 2015.